Compare Regeneron Pharmaceuticals Inc (REGN) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Yum China Holdings Inc trades at $42.34 (market cap $14.74B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.7× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.68%). Which is the better fit depends on your goals.
| REGN | YUMC | |
|---|---|---|
Market Cap | $83.43B | $14.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $57.95 |
52-Week Low | $555.51 | $40.18 |
Enterprise Value | $78.14B | $15.65B |
Dividend Yield | 0.46% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
YUMC trades at $43.34, down 0.6% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth, reaching $11.8B in 2025, with a net income margin of 7.84%. Recent developments include the acquisition of Pizza Hut brand ownership in Mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is positive with strong analyst support—14 buy ratings and a projected 25.6% upside. Risks include competitive pressures and market volatility, but solid fundamentals and growth initiatives provide a compelling case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
